Farxiga Cost in Arkansas 2026: Cash Price, Medicaid, Compounded Options

What Does Farxiga Actually Cost in Arkansas Right Now?

The manufacturer list price for Farxiga (dapagliflozin 10 mg, 30-tablet pack) sits at approximately $620 per month in 2026 across Arkansas retail chains such as Walmart, Walgreens, CVS, and independent pharmacies. That figure reflects AstraZeneca's wholesale acquisition cost and does not include dispensing fees, which add $2 to $15 depending on the pharmacy. Without insurance or a savings program, most Arkansans filling a 30-day supply at the counter pay close to that $620 sticker price.

No FDA-approved generic dapagliflozin existed as of mid-2025, which keeps the cash price high relative to older diabetes agents like metformin or glipizide. AstraZeneca holds multiple patents on the dapagliflozin molecule and its tablet formulations; the earliest realistic generic entry is not expected until late 2025 or 2026 depending on patent litigation outcomes. Patients who are uninsured or whose insurance does not cover SGLT2 inhibitors have three practical routes to lower cost: manufacturer savings programs, GoodRx-style discount cards, and compounded dapagliflozin from a licensed 503A pharmacy.

GoodRx and similar discount platforms typically show Arkansas prices between $540 and $590 for a 30-day supply of brand Farxiga when a coupon code is applied at participating pharmacies. These prices fluctuate weekly, so checking the platform on the day of fill is advisable. Discount cards cannot be combined with insurance or Medicaid.

The FDA's label for Farxiga covers type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) with or without T2DM. FDA Farxiga prescribing information Each approved indication affects how insurers and Medicaid programs classify the drug on their formularies, which directly shapes what an Arkansas patient pays out of pocket.

How Arkansas Medicaid Covers Farxiga in 2026

Arkansas Medicaid (Arkansas DHS, Division of Medical Services) covers Farxiga for type 2 diabetes, heart failure, and chronic kidney disease, but requires a prior authorization (PA) in every case. The PA process means a prescriber must submit clinical documentation showing the patient meets specific criteria before the pharmacy claim is approved.

For the T2DM indication, Arkansas Medicaid generally requires documentation that the patient has tried and either not tolerated or not achieved target glycemic control on metformin at a maximally tolerated dose. For the heart failure indication, evidence of a reduced ejection fraction (typically EF <40%) supported by an echocardiogram report is standard. CKD coverage typically requires a documented eGFR between 25 and 75 mL/min/1.73 m² along with a urine albumin-to-creatinine ratio (UACR) above 200 mg/g, consistent with CREDENCE and DAPA-CKD trial enrollment criteria.

The Endocrine Society's 2023 clinical practice guideline states that SGLT2 inhibitors should be recommended for patients with T2DM and established cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c, given their cardiorenal protective effects independent of glucose lowering. Endocrine Society 2023 Diabetes Guidelines Arkansas Medicaid's PA criteria have gradually aligned with this evidence base, though prior authorizations still add a 3 to 10 business day delay for most patients.

Patients enrolled in Arkansas Medicaid Managed Care (currently administered by Help Healthcare Solutions, Summit Community Care, and Arkansas Total Care) may face slightly different formulary tiers and PA templates depending on their plan. Calling the plan's pharmacy services line before the prescriber submits the PA avoids surprises at the counter.

The AstraZeneca Savings Card and Patient Assistance Programs

AstraZeneca offers two separate affordability programs for Farxiga that Arkansas residents can use, depending on insurance status.

The Farxiga Savings Card is for commercially insured patients only. Eligible patients may pay $0 per month for up to 12 months, with an annual savings cap that AstraZeneca has set at $3,600 as of 2025. Government-insured patients, including those on Arkansas Medicaid or Medicare Part D, are not eligible. Enrollment takes about five minutes at AstraZeneca's website, and the card works at most major Arkansas chain pharmacies.

AstraZeneca's AZ&Me Prescription Savings Program covers patients who are uninsured or underinsured and meet income thresholds. As of 2025, household income at or below 600% of the federal poverty level may qualify for free or deeply discounted Farxiga. Arkansas residents can apply online or by phone. Processing typically takes two to four weeks for the first fill, so starting the application before the current supply runs out is wise.

Neither program applies to Medicaid beneficiaries because federal anti-kickback rules prohibit manufacturers from subsidizing cost-sharing for government programs. Arkansas Medicare Part D beneficiaries should ask their plan about the Low Income Subsidy (LIS/Extra Help) program, which can reduce Farxiga cost-sharing to $0 or a small copay depending on the formulary tier.

Compounded Dapagliflozin in Arkansas: What Is Legal, What Is Not

Compounded dapagliflozin occupies a specific legal space in Arkansas. State pharmacy law permits 503A compounding pharmacies to prepare patient-specific compounded medications, and dapagliflozin is not on the FDA's list of drugs that are categorically prohibited from compounding. A licensed Arkansas 503A pharmacy can therefore prepare compounded dapagliflozin for an individual patient with a valid prescription from a licensed prescriber.

This is categorically different from 503B outsourcing facilities, which produce large batches of compounded drugs primarily for hospitals and clinics. 503B facilities are subject to stricter FDA oversight, and dapagliflozin has not been placed on FDA's 503B "bulk drug substances" list. Arkansas patients sourcing compounded dapagliflozin should confirm they are receiving product from a state-licensed 503A pharmacy, not an unlicensed online vendor.

The Arkansas State Board of Pharmacy maintains a public license-verification tool at pharmacy.arkansas.gov. Patients and prescribers should verify any compounding pharmacy's active license before placing an order. A pharmacy that cannot provide its Arkansas Board of Pharmacy license number and proof of compliance with USP <795> standards for non-sterile compounding should be avoided.

Cash pricing for compounded dapagliflozin at Arkansas 503A pharmacies varies considerably. Some HealthRX partner pharmacies in the state have quoted monthly costs between $60 and $120 for a compounded dapagliflozin preparation, compared with the $620 brand list price. These prices are not standardized and depend on the compounding pharmacy's overhead, ingredient sourcing, and dispensing model.

One clinical consideration: compounded dapagliflozin has not been tested in the large outcomes trials that built the drug's evidence base. The DAPA-HF trial enrolled 4,744 patients with HFrEF and showed that dapagliflozin 10 mg once daily reduced the composite of CV death, worsening heart failure, or urgent heart failure visit by 26% relative to placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001). DAPA-HF, NEJM 2019 Those results were generated with AstraZeneca's branded formulation. Whether a compounded preparation delivers equivalent bioavailability has not been validated in any published pharmacokinetic study. Prescribers and patients should weigh this uncertainty explicitly.

Why Dapagliflozin's Evidence Base Justifies the Cost Conversation

Understanding why Farxiga commands a $620 list price requires looking at the breadth of outcomes data behind it. The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, CV death, or renal death by 39% versus placebo in patients with CKD and albuminuria, with a hazard ratio of 0.61 (95% CI 0.51 to 0.72). DAPA-CKD, NEJM 2020 That magnitude of benefit in a hard renal endpoint is rare for any drug class.

For glycemic control in T2DM, the DECLARE-TIMI 58 trial (N=17,160) demonstrated that dapagliflozin reduced the rate of hospitalization for heart failure or cardiovascular death compared with placebo in a broad T2DM population. DECLARE-TIMI 58, NEJM 2019 Arkansas has one of the highest rates of T2DM in the United States: the CDC estimates that 13.0% of Arkansas adults had diagnosed diabetes in 2021, above the national average of 11.3%. CDC Diabetes Surveillance 2021 That prevalence means Farxiga's cost question affects a large share of the state's population.

The American Diabetes Association's 2024 Standards of Care give a Grade A recommendation for SGLT2 inhibitors in patients with T2DM and heart failure or CKD, stating: "In patients with type 2 diabetes and established heart failure with reduced ejection fraction, an SGLT2 inhibitor with proven benefit should be prescribed to reduce risk of worsening heart failure and cardiovascular death." ADA Standards of Care 2024 When a drug carries that recommendation level across multiple guideline bodies, insurance non-coverage or PA delays carry real clinical consequences.

Getting Farxiga via Telehealth in Arkansas

Arkansas permits telehealth prescribing for non-controlled prescription medications, and dapagliflozin qualifies. A telehealth prescriber licensed in Arkansas can evaluate a patient via synchronous audio-video visit and issue a valid Farxiga prescription that any Arkansas pharmacy will fill.

HealthRX clinicians conduct Arkansas telehealth visits and can assess eligibility for Farxiga across all three approved indications. The standard intake process includes a review of recent labs (HbA1c, BMP for eGFR and creatinine, urine albumin if CKD is a concern), current medication list, and prior authorization history if the patient is on Arkansas Medicaid. Most initial visits are completed in 20 to 30 minutes; follow-up visits for dose adjustment or lab review typically run 10 to 15 minutes.

One practical advantage of telehealth prescribing for Farxiga is that the prescriber can simultaneously initiate the AstraZeneca savings card enrollment or prepare the PA documentation for Medicaid within the visit, shortening the time from evaluation to first fill. Patients in rural Arkansas counties, where endocrinologists and cardiologists may be hours away, benefit most from this model. Approximately 42% of Arkansas's 75 counties are classified as Health Professional Shortage Areas for primary care. HRSA HPSA Data 2024

Prior Authorization Strategy: Getting Farxiga Approved Faster

Prior authorization denials for Farxiga in Arkansas most often occur for one of three reasons: missing lab documentation, failure to document a metformin trial (for T2DM indication), or submission to the wrong PA pathway (some Medicaid managed care plans have a separate cardiology PA pathway for the HF indication versus the diabetes pathway).

Prescribers submitting a PA for the CKD indication should include the most recent eGFR value, a UACR result, and the diagnosis code for CKD stage (ICD-10 codes N18.3 or N18.4 are most commonly accepted for the dapagliflozin CKD indication). Submitting without the UACR result is the single most common reason for a first-pass denial at Arkansas Medicaid managed care plans.

For the heart failure indication, an echocardiogram report documenting EF <40% should accompany the PA. If the echo was performed more than 12 months ago, some plans request a repeat study. Prescribers aware of this requirement can order the echo proactively rather than waiting for a denial-and-appeal cycle, which adds 15 to 30 days of delay.

Appeals for denied PAs have a meaningful success rate when the clinical documentation is complete. Arkansas Medicaid policy requires a decision on standard PA requests within three business days and on expedited requests within 24 hours when the prescriber certifies that the standard timeline would seriously jeopardize the patient's health.

Comparing Dapagliflozin to Other Arkansas-Covered SGLT2 Inhibitors

Arkansas Medicaid and most commercial plans in the state also cover empagliflozin (Jardiance) and canagliflozin (Invokana), the two other SGLT2 inhibitors with major outcomes data. All three require PA. In many commercial formularies, one SGLT2 inhibitor is placed on a preferred tier while the others are non-preferred, meaning co-pays differ.

Empagliflozin's EMPEROR-Reduced trial (N=3,730) showed similar relative risk reduction in the heart failure composite endpoint to DAPA-HF: a 25% reduction in CV death or worsening heart failure hospitalization. EMPEROR-Reduced, NEJM 2020 The drugs are considered therapeutically interchangeable by most cardiology and endocrinology guidelines for patients with overlapping T2DM and HF. If an Arkansas insurer places empagliflozin on a preferred tier with a lower co-pay, switching may be reasonable after discussion with the prescriber, provided the patient lacks a specific clinical reason to stay on dapagliflozin (such as CKD, where the DAPA-CKD data are uniquely strong).

Canagliflozin carries an FDA black box warning for lower-limb amputation risk based on the CANVAS program. CANVAS, NEJM 2017 That warning does not apply to dapagliflozin or empagliflozin, and most prescribers avoid canagliflozin in patients with peripheral artery disease or prior amputation.

Cost Reduction Checklist for Arkansas Patients

Patients paying full cash price for Farxiga in Arkansas have several concrete steps available before accepting the $620 monthly cost:

1. Check commercial insurance formulary tier and confirm whether a PA has been filed. Many patients have coverage they have not activated.
2. If commercially insured and eligible, enroll in the AstraZeneca savings card at the pharmacy counter or online before the next fill.
3. If uninsured or underinsured, apply for AZ&Me. Processing takes two to four weeks, so start before the current 30-day supply ends.
4. Ask the prescriber whether empagliflozin is on a preferred formulary tier with the patient's specific plan. The clinical difference is minor for most patients.
5. Check GoodRx, RxSaver, and Cost Plus Drugs prices at local Arkansas pharmacies. Mark Cuban's Cost Plus Drugs does not currently stock brand Farxiga, but this can change.
6. Ask a HealthRX clinician about compounded dapagliflozin from a licensed 503A pharmacy if cash cost remains prohibitive after exhausting brand savings programs. Confirm the pharmacy's Arkansas Board of Pharmacy license before ordering.